Originally published as JCO Early Release 10.1200/JCO.2003.03.189 on April 11 2003
Journal of Clinical Oncology, Vol 21, Issue 12
(June), 2003: 2397-2406
© 2003 American Society for Clinical Oncology
American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility
Adopted on March 1, 2003, by the American Society Of Clinical Oncology
Address reprint requests to Suanna S. Bruinooge, American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke Street, Suite 200, Alexandria, VA, 22314; email: bruinoos{at}asco.org.
Executive Summary: As the leading organization representing cancer specialists involved in patient care and clinical research, the American Society of Clinical Oncology (ASCO) reaffirms its commitment to integrating cancer risk assessment and management, including molecular analysis of cancer predisposition genes, into the practice of oncology and preventive medicine. The primary goal of this effort is to foster expanded access to, and continued advances in, medical care provided to patients and families affected by hereditary cancer syndromes. The 1996 ASCO Statement on Genetic Testing for Cancer Susceptibility set forth specific recommendations relating to clinical practice, research needs, educational opportunities, requirement for informed consent, indications for genetic testing, regulation of laboratories, and protection from discrimination, as well as access to and reimbursement for cancer genetics services. In updating this Statement, ASCO endorses the following principles:
- Indications for Genetic Testing:ASCO recommends that genetic testing be offered when 1) the individual has personal or family history features suggestive of a genetic cancer susceptibility condition, 2) the test can be adequately interpreted, and 3) the results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer. ASCO recommends that genetic testing only be done in the setting of pre- and post-test counseling, which should include discussion of possible risks and benefits of cancer early detection and prevention modalities.
- Special Issues in Testing Children for Cancer Susceptibility:ASCO recommends that the decision to offer testing to potentially affected children should take into account the availability of evidence-based risk-reduction strategies and the probability of developing a malignancy during childhood. Where risk-reduction strategies are available or cancer predominantly develops in childhood, ASCO believes that the scope of parental authority encompasses the right to decide for or against testing. In the absence of increased risk of a childhood malignancy, ASCO recommends delaying genetic testing until an individual is of sufficient age to make an informed decision regarding such tests. As in other areas of pediatric care, the clinical cancer genetics professional should be an advocate for the best interests of the child.
- Counseling About Medical Management After Testing:ASCO recommends that oncologists include in pre- and post-test counseling the discussion of possible risks and benefits of cancer early-detection and prevention modalities, some of which have presumed but unproven efficacy for individuals at increased hereditary risk of cancer.
- Regulation of Genetic Testing:ASCO recommends strengthening regulatory oversight of laboratories that provide clinical cancer predisposition tests. These quality assurance mechanisms should include oversight of the reagents used in genetic testing, interlaboratory comparisons of reference samples, standardization of laboratory genetic test reports, and proficiency testing.
- Protection From Insurance and Employment Discrimination:ASCO supports establishing a federal law to prohibit discrimination by health insurance providers and employers on the basis of an individual’s inherited susceptibility to cancer. Protections against genetic discrimination should apply to those with group coverage, those with individual health insurance policies, and the uninsured.
- Coverage of Services:ASCO supports efforts to ensure that all individuals at significantly increased risk of hereditary cancer have access to appropriate genetic counseling, testing, screening, surveillance, and all related medical and surgical interventions, which should be covered without penalty by public and private third-party payers.
- Confidentiality and Communication of Familial Risk:ASCO recommends that providers make concerted efforts to protect the confidentiality of genetic information. However, they should remind patients of the importance of communicating test results to family members, as part of pretest counseling and informed consent discussions. ASCO believes that the cancer care provider’s obligations (if any) to at-risk relatives are best fulfilled by communication of familial risk to the person undergoing testing, emphasizing the importance of sharing this information with family members so that they may also benefit.
- Educational Opportunities in Genetics:ASCO is committed to continuing to provide educational opportunities for physicians and other health care providers regarding the methods of cancer risk assessment, the clinical characteristics of hereditary cancer susceptibility syndromes, and the range of issues related to genetic testing, including pre- and post-test genetic counseling, and risk management, so that health professionals may responsibly integrate the care of persons at increased genetic risk of cancer into the practice of clinical and preventive oncology.
- Special Issues Relating to Genetic Research on Human Tissues:ASCO recommends that all researchers proposing to use or store human biologic specimens for genetic studies should consult either the responsible institutional review board (IRB) or a comparable body specifically constituted to assess human tissue research, to determine the requirements for protection specific to the study under consideration. This consultation should take place before the project is initiated. The determination of the need for informed consent or authorization in such studies should depend on whether the research involves tests for genetic markers of known clinical significance and whether research data will be linked to protected health information, as well as other considerations specific to the study proposed. Special attention should also be paid to 1) whether future research findings will be disclosed to the research participants, 2) whether future contact of participants is planned, 3) whether and how protected health information about the tissue donors will be stored, and what will happen to study specimens after the trial ends. In addition, ASCO affirms the right of people contributing tissue to a databank to rescind their permission, in accordance with federal privacy regulations.
ASCO sincerely appreciates the contributions of the ASCO Working Group on Genetic Testing for Cancer Susceptibility, which devoted time and effort to this project. The Working Group was chaired by Kennith Offit, MD, MPH, Memorial Sloan-Kettering Cancer Center. A list of Working Group members appears in the Acknowledgement section.
This article has been cited by other articles:
|
|
|
|
 
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem.,
December 1, 2008;
54(12):
e11 - e79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Mahoney, T. Bevers, E. Linos, and W. C. Willett
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
CA Cancer J Clin,
November 3, 2008;
(2008)
CA.2008.0016v1.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Integrating Genetic Risk Assessment Into Practice
J. Oncol. Pract,
September 1, 2008;
4(5):
214 - 219.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Storm, R. Agarwal, and K. Offit
Ethical and Legal Implications of Cancer Genetic Testing: Do Physicians Have a Duty to Warn Patients' Relatives About Possible Genetic Risks?
J. Oncol. Pract,
September 1, 2008;
4(5):
229 - 230.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Allain
Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2008;
10(5):
383 - 395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A W Cappelen, O F Norheim, and B Tungodden
Genomics and equal opportunity ethics
J. Med. Ethics,
May 1, 2008;
34(5):
361 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Peshkin, T. A. DeMarco, J. E. Garber, H. B. Valdimarsdottir, A. F. Patenaude, K. A. Schneider, M. D. Schwartz, and K. P. Tercyak
Brief Assessment of Parents' Attitudes Toward Testing Minor Children for Hereditary Breast/Ovarian Cancer Genes: Development and Validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS)
J. Pediatr. Psychol.,
April 1, 2008;
(2008)
jsn033v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Goss
Genetic Testing for Cancer: Legal, Ethical, and Practical Issues for the Practicing Oncologist
J. Oncol. Pract,
March 1, 2008;
4(2):
64 - 65.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Genetic Counseling: An Indispensable Step in the Genetic Testing Process
J. Oncol. Pract,
March 1, 2008;
4(2):
96 - 98.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Chan-Smutko, D. Patel, K. M. Shannon, and P. D. Ryan
Professional Challenges in Cancer Genetic Testing: Who Is the Patient?
Oncologist,
March 1, 2008;
13(3):
232 - 238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hemminki, J. Sundquist, and J. Lorenzo Bermejo
Familial Risks for Cancer as the Basis for Evidence-Based Clinical Referral and Counseling
Oncologist,
March 1, 2008;
13(3):
239 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Morrison, E. P. Winer, J. Harris, and B. L. Smith
Case 32-2007: Bilateral Breast Cancer
N. Engl. J. Med.,
February 28, 2008;
358(9):
970 - 970.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Weitzel, V. I. Lagos, and D. J. MacDonald
Limited Family Structure and Breast Cancer Risk Reply
JAMA,
November 7, 2007;
298(17):
2007 - 2008.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Aktan-Collan, A Haukkala, K Pylvanainen, H J Jarvinen, L A Aaltonen, P Peltomaki, E Rantanen, H Kaariainen, and J-P Mecklin
Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing
J. Med. Genet.,
November 1, 2007;
44(11):
732 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Parmigiani, S. Chen, E. S. Iversen Jr, T. M. Friebel, D. M. Finkelstein, H. Anton-Culver, A. Ziogas, B. L. Weber, A. Eisen, K. E. Malone, et al.
Validity of Models for Predicting BRCA1 and BRCA2 Mutations
Ann Intern Med,
October 2, 2007;
147(7):
441 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E Brand, M. M Lerch, W. S Rubinstein, J. P Neoptolemos, D. C Whitcomb, R. H Hruban, T. A Brentnall, H. T Lynch, M. I Canto, and Participants of the Fourth International Symposium
Advances in counselling and surveillance of patients at risk for pancreatic cancer
Gut,
October 1, 2007;
56(10):
1460 - 1469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Bradbury, J. J. Dignam, C. N. Ibe, S. L. Auh, F. J. Hlubocky, S. A. Cummings, M. White, O. I. Olopade, and C. K. Daugherty
How Often Do BRCA Mutation Carriers Tell Their Young Children of the Family's Risk for Cancer? A Study of Parental Disclosure of BRCA Mutations to Minors and Young Adults
J. Clin. Oncol.,
August 20, 2007;
25(24):
3705 - 3711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Hamilton and B. J. Bowers
The Theory of Genetic Vulnerability: A Roy Model Exemplar
Nurs Sci Q,
July 1, 2007;
20(3):
254 - 264.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Y. Karlan, A. Berchuck, and D. Mutch
The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice
Obstet. Gynecol.,
July 1, 2007;
110(1):
155 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald
Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer
JAMA,
June 20, 2007;
297(23):
2587 - 2595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Kauff and K. Offit
Modeling Genetic Risk of Breast Cancer
JAMA,
June 20, 2007;
297(23):
2637 - 2639.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Edlefsen, J. F. Tait, M. H. Wener, and M. Astion
Utilization and Diagnostic Yield of Neurogenetic Testing at a Tertiary Care Facility
Clin. Chem.,
June 1, 2007;
53(6):
1016 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Peshkin, R. H. Nusbaum, and T. A. DeMarco
Genetic Counseling About Reproductive Options for Hereditary Cancer: What Is the Standard of Care?
J. Clin. Oncol.,
March 1, 2007;
25(7):
911 - 912.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Saslow, C. Boetes, W. Burke, S. Harms, M. O. Leach, C. D. Lehman, E. Morris, E. Pisano, M. Schnall, S. Sener, et al.
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
CA Cancer J Clin,
March 1, 2007;
57(2):
75 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Tercyak, B. N. Peshkin, B. M. Brogan, T. DeMarco, M. F. Pennanen, S. C. Willey, C. M. Magnant, S. Rogers, C. Isaacs, and M. D. Schwartz
Quality of Life After Contralateral Prophylactic Mastectomy in Newly Diagnosed High-Risk Breast Cancer Patients Who Underwent BRCA1/2 Gene Testing
J. Clin. Oncol.,
January 20, 2007;
25(3):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dorval, M.-H. Vallee, M. Plante, J. Chiquette, M. Gaudet, the Interdisciplinary Health Research Internationa, J. Simard, and the Interdisciplinary Health Research Internationa
Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2007;
16(1):
157 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Offit, M. Sagi, and K. Hurley
Preimplantation Genetic Diagnosis for Cancer Syndromes: A New Challenge for Preventive Medicine
JAMA,
December 13, 2006;
296(22):
2727 - 2730.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Ganz
Monitoring the Physical Health of Cancer Survivors: A Survivorship-Focused Medical History
J. Clin. Oncol.,
November 10, 2006;
24(32):
5105 - 5111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Agulnik, A. M. Oza, G. R. Pond, and L. L. Siu
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents
J. Clin. Oncol.,
October 20, 2006;
24(30):
4801 - 4807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chen, W. Wang, S. Lee, K. Nafa, J. Lee, K. Romans, P. Watson, S. B. Gruber, D. Euhus, K. W. Kinzler, et al.
Prediction of germline mutations and cancer risk in the Lynch syndrome.
JAMA,
September 27, 2006;
296(12):
1479 - 1487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Loud, N. E. Weissman, J. A. Peters, R. M. Giusti, B. S. Wilfond, W. Burke, and M. H. Greene
Deliberate Deceit of Family Members: A Challenge to Providers of Clinical Genetics Services
J. Clin. Oncol.,
April 1, 2006;
24(10):
1643 - 1646.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dorval, G. Gauthier, E. Maunsell, M. J. Dugas, I. Rouleau, J. Chiquette, M. Plante, R. Laframboise, M. Gaudet, P. J. Bridge, et al.
No Evidence of False Reassurance among Women with an Inconclusive BRCA1/2 Genetic Test Result
Cancer Epidemiol. Biomarkers Prev.,
December 1, 2005;
14(12):
2862 - 2867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Cass, C. Holschneider, N. Datta, D. Barbuto, A. E. Walts, and B. Y. Karlan
BRCA-Mutation-Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype?
Obstet. Gynecol.,
December 1, 2005;
106(6):
1327 - 1334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Halbert, K. Brewster, A. Collier, C. Smith, L. Kessler, B. Weathers, J. E. Stopfer, S. Domchek, and E. P. Wileyto
Recruiting African American Women to Participate in Hereditary Breast Cancer Research
J. Clin. Oncol.,
November 1, 2005;
23(31):
7967 - 7973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nanda, L. P. Schumm, S. Cummings, J. D. Fackenthal, L. Sveen, F. Ademuyiwa, M. Cobleigh, L. Esserman, N. M. Lindor, S. L. Neuhausen, et al.
Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African Ancestry
JAMA,
October 19, 2005;
294(15):
1925 - 1933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Wideroff, S T Vadaparampil, M H Greene, S Taplin, L Olson, and A N Freedman
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians
J. Med. Genet.,
October 1, 2005;
42(10):
749 - 755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Weitzel, V. Lagos, K. R. Blazer, R. Nelson, C. Ricker, J. Herzog, C. McGuire, and S. Neuhausen
Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2005;
14(7):
1666 - 1671.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Gritz, S. K. Peterson, S. W. Vernon, S. K. Marani, W. F. Baile, B. G. Watts, C. I. Amos, M. L. Frazier, and P. M. Lynch
Psychological Impact of Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer
J. Clin. Oncol.,
March 20, 2005;
23(9):
1902 - 1910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Patterson, L. D. Robinson, E. Z. Naftalis, B. B. Haley, and G. E. Tomlinson
Custodianship of Genetic Information: Clinical Challenges and Professional Responsibility
J. Clin. Oncol.,
March 20, 2005;
23(9):
2100 - 2104.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Narod and K. Offit
Prevention and Management of Hereditary Breast Cancer
J. Clin. Oncol.,
March 10, 2005;
23(8):
1656 - 1663.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Garber and K. Offit
Hereditary Cancer Predisposition Syndromes
J. Clin. Oncol.,
January 10, 2005;
23(2):
276 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Offit
MSH6 Mutations in Hereditary Nonpolyposis Colon Cancer: Another Slice of the Pie
J. Clin. Oncol.,
November 15, 2004;
22(22):
4449 - 4451.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sifri, S. Gangadharappa, and L. S. Acheson
Identifying and Testing for Hereditary Susceptibility to Common Cancers
CA Cancer J Clin,
November 1, 2004;
54(6):
309 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Hemminki and C Eng
Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans
J. Med. Genet.,
November 1, 2004;
41(11):
801 - 807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Halbert, H. Lynch, J. Lynch, D. Main, S. Kucharski, A. K. Rustgi, and C. Lerman
Colon Cancer Screening Practices Following Genetic Testing for Hereditary Nonpolyposis Colon Cancer (HNPCC) Mutations
Arch Intern Med,
September 27, 2004;
164(17):
1881 - 1887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Offit, E. Groeger, S. Turner, E. A. Wadsworth, and M. A. Weiser
The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks
JAMA,
September 22, 2004;
292(12):
1469 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Murff, D. R. Spigel, and S. Syngal
Does This Patient Have a Family History of Cancer?: An Evidence-Based Analysis of the Accuracy of Family Cancer History
JAMA,
September 22, 2004;
292(12):
1480 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Schneider, A. M. Epstein, J. L. Malin, K. L. Kahn, and E. J. Emanuel
Developing a System to Assess the Quality of Cancer Care: ASCO's National Initiative on Cancer Care Quality
J. Clin. Oncol.,
August 1, 2004;
22(15):
2985 - 2991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Green, S. K. Peterson, M. W. Baker, G. R. Harper, L. C. Friedman, W. S. Rubinstein, and D. T. Mauger
Effect of a Computer-Based Decision Aid on Knowledge, Perceptions, and Intentions About Genetic Testing for Breast Cancer Susceptibility: A Randomized Controlled Trial
JAMA,
July 28, 2004;
292(4):
442 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K R Blazer, M Grant, S R Sand, D J MacDonald, G C Uman, and J N Weitzel
Effects of a cancer genetics education programme on clinician knowledge and practice
J. Med. Genet.,
July 1, 2004;
41(7):
518 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Osborne, P. Wilson, and D. Tripathy
Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications
Oncologist,
July 1, 2004;
9(4):
361 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Schwartz, C. Lerman, B. Brogan, B. N. Peshkin, C. Hughes Halbert, T. DeMarco, W. Lawrence, D. Main, C. Finch, C. Magnant, et al.
Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients
J. Clin. Oncol.,
May 15, 2004;
22(10):
1823 - 1829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Halbert, L. Wenzel, C. Lerman, B. N. Peshkin, S. Narod, A. Marcus, C. Corio, T. Demarco, and S. Bellamy
Predictors of Participation in Psychosocial Telephone Counseling following Genetic Testing for BRCA1 and BRCA2 Mutations
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2004;
13(5):
875 - 881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Contegiacomo, M. Pensabene, I. Capuano, L. Tauchmanova, M. Federico, D. Turchetti, L. Cortesi, P. Marchetti, E. Ricevuto, G. Cianci, et al.
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer
Ann. Onc.,
May 1, 2004;
15(5):
726 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Thull and V. G. Vogel
Recognition and Management of Hereditary Breast Cancer Syndromes
Oncologist,
February 1, 2004;
9(1):
13 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
